Fierce Biotech Webinar: Plasmid Platform Facilitates Transition to Clinic

March 24, 2022

Biological therapeutic research depends on plasmid DNA, from early pilot studies to preparations for GMP manufacturing. Therefore, it is essential to have a reliable supply for Plasmid DNA at all points of the drug development life cycle. In an upcoming Fierce Biotech Webinar next week on Tuesday, march 29^th, Matthias Craig, PhD, of Catalent Cell and Gene Therapy, will explain how securing plasmid production services early on can expedite the process towards GMP manufacturing.

“Matthias Craig, Ph.D., joined Catalent Cell & Gene Therapy through its acquisition of Delphi Genetics in 2021 and is currently the Sr. Manager Product Development focused on plasmid DNA. Prior to Catalent, he spent seven years in several roles at Eurogentec, including project lead, new technology development scientist, and business development for projects related to the production of recombinant proteins and plasmids. He has a doctorate in Molecular Biology and a Master’s in Biology from the University of Liège, Belgium.”